Wenjian Min

818 total citations
36 papers, 507 citations indexed

About

Wenjian Min is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wenjian Min has authored 36 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 11 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wenjian Min's work include Advanced Breast Cancer Therapies (6 papers), Cancer Mechanisms and Therapy (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Wenjian Min is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Cancer Mechanisms and Therapy (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Wenjian Min collaborates with scholars based in China, United States and Poland. Wenjian Min's co-authors include Peng Yang, Kai Yuan, Xiao Wang, Haiping Hao, Yi Hou, Xiaojia Liu, Chengliang Sun, Yibei Xiao, Hongbin Deng and Yasheng Zhu and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Medicinal Chemistry.

In The Last Decade

Wenjian Min

32 papers receiving 504 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wenjian Min China 14 255 190 114 82 62 36 507
Kai Yuan China 13 218 0.9× 199 1.0× 91 0.8× 168 2.0× 61 1.0× 36 603
Yue-Li Sun China 10 248 1.0× 230 1.2× 59 0.5× 31 0.4× 42 0.7× 23 535
Shengyong Yang China 13 187 0.7× 103 0.5× 48 0.4× 73 0.9× 36 0.6× 18 356
Christopher Toth United States 11 229 0.9× 211 1.1× 54 0.5× 57 0.7× 132 2.1× 15 586
Aakanksha Khandelwal United States 11 276 1.1× 81 0.4× 127 1.1× 62 0.8× 51 0.8× 14 488
Min‐Wu Chao Taiwan 15 364 1.4× 149 0.8× 31 0.3× 86 1.0× 37 0.6× 26 492
Karsten Denner Germany 11 323 1.3× 108 0.6× 93 0.8× 55 0.7× 94 1.5× 19 660
Swarupa G. Kulkarni United States 10 507 2.0× 293 1.5× 103 0.9× 52 0.6× 42 0.7× 17 754
Sung Yun Cho South Korea 15 356 1.4× 115 0.6× 66 0.6× 277 3.4× 81 1.3× 43 673

Countries citing papers authored by Wenjian Min

Since Specialization
Citations

This map shows the geographic impact of Wenjian Min's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenjian Min with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenjian Min more than expected).

Fields of papers citing papers by Wenjian Min

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenjian Min. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenjian Min. The network helps show where Wenjian Min may publish in the future.

Co-authorship network of co-authors of Wenjian Min

This figure shows the co-authorship network connecting the top 25 collaborators of Wenjian Min. A scholar is included among the top collaborators of Wenjian Min based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenjian Min. Wenjian Min is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Min, Wenjian, Yi Hou, Dawei Wang, et al.. (2025). Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein–Protein Interaction. Journal of Medicinal Chemistry. 68(2). 1844–1862. 6 indexed citations
2.
Chen, Yuanyuan, et al.. (2025). Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment. Chinese Journal of Natural Medicines. 23(3). 286–298. 2 indexed citations
3.
Hou, Yi, Qin Han, Xiao Zheng, et al.. (2025). Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy. Journal of Medicinal Chemistry. 68(22). 24404–24423.
4.
Min, Wenjian, Chunling Chen, Yan Zhao, et al.. (2025). Discovery of a Novel and Potent MET Transcription Inhibitor Targeting Promoter G-Quadruplex for the Treatment of NSCLC. Journal of Medicinal Chemistry. 68(11). 10845–10859.
5.
Gui, Yuan, Haiyan Fu, Jianling Tao, et al.. (2024). Fibroblast expression of transmembrane protein smoothened governs microenvironment characteristics after acute kidney injury. Journal of Clinical Investigation. 134(13). 7 indexed citations
6.
Li, Jiaxing, Yiwen Zhang, Wenjian Min, et al.. (2024). ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis. Leukemia. 39(3). 599–613. 5 indexed citations
7.
Sun, Chengliang, Yao Cheng, Jingwen Dong, et al.. (2024). Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents. Journal of Medicinal Chemistry. 68(1). 156–173. 3 indexed citations
8.
Min, Wenjian, Dawei Wang, Chunling Chen, et al.. (2024). Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment. Journal of Medicinal Chemistry. 67(14). 12314–12330. 6 indexed citations
9.
Yuan, Kai, Hongtao Shen, Zeyu Cai, et al.. (2023). Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry. 66(6). 4215–4230. 10 indexed citations
10.
Zhang, Haoling, Mingming Zheng, Wenjian Min, et al.. (2023). Targeting polyketide synthase 13 for the treatment of tuberculosis. European Journal of Medicinal Chemistry. 259. 115702–115702. 6 indexed citations
11.
Min, Wenjian, Hongtao Shen, Tong Chen, et al.. (2023). Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment. European Journal of Medicinal Chemistry. 264. 116025–116025. 5 indexed citations
12.
Li, Jiemei, Jing Niu, Wenjian Min, et al.. (2022). B7-1 mediates podocyte injury and glomerulosclerosis through communication with Hsp90ab1-LRP5-β-catenin pathway. Cell Death and Differentiation. 29(12). 2399–2416. 20 indexed citations
13.
Hou, Yi, Fang Zhang, Wenjian Min, et al.. (2022). Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer. Journal of Medicinal Chemistry. 65(14). 9873–9892. 12 indexed citations
14.
Sun, Chengliang, Yao Cheng, Xiaojia Liu, et al.. (2022). Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. Acta Pharmaceutica Sinica B. 12(12). 4446–4457. 25 indexed citations
15.
Cheng, Hao, Wenjian Min, Xiao Wang, et al.. (2022). Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer. Journal of Medicinal Chemistry. 65(22). 15102–15122. 11 indexed citations
16.
Li, Jiaxing, Xiao Wang, Yasheng Zhu, et al.. (2021). Development and clinical advancement of small molecules for ex vivo expansion of hematopoietic stem cell. Acta Pharmaceutica Sinica B. 12(6). 2808–2831. 12 indexed citations
17.
Yuan, Kai, Wenbin Kuang, Wenjian Min, et al.. (2021). Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. European Journal of Medicinal Chemistry. 228. 114024–114024. 10 indexed citations
18.
Yuan, Kai, Shengnan Xie, Zhixia Qiu, et al.. (2021). Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 65(1). 857–875. 13 indexed citations
19.
Yuan, Kai, et al.. (2020). Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharmaceutica Sinica B. 11(1). 30–54. 103 indexed citations
20.
Min, Wenjian, Rukang Zhang, Yuan‐Qing Li, et al.. (2020). Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(9). 127061–127061. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kai Yuan Breakdown of academic impact, for papers by Yue-Li Sun Breakdown of academic impact, for papers by Shengyong Yang Breakdown of academic impact, for papers by Christopher Toth Breakdown of academic impact, for papers by Aakanksha Khandelwal Breakdown of academic impact, for papers by Min‐Wu Chao Breakdown of academic impact, for papers by Karsten Denner Breakdown of academic impact, for papers by Swarupa G. Kulkarni Breakdown of academic impact, for papers by Sung Yun Cho
Rankless by CCL
2026